168 related articles for article (PubMed ID: 28737985)
1. Evaluation of Patient Migration Patterns and Related Health Care Costs Within a National Medicare Advantage Prescription Drug Plan After Implementation of an Oxycodone HCl Extended-Release Access Restriction.
Chen CC; De AP; Sweet B; Wade RL
J Manag Care Spec Pharm; 2017 Aug; 23(8):902-912. PubMed ID: 28737985
[TBL] [Abstract][Full Text] [Related]
2. Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans.
Wade RL; Chen CC; De AP; Howard JC
J Health Econ Outcomes Res; 2017; 5(1):75-88. PubMed ID: 37664692
[No Abstract] [Full Text] [Related]
3. Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a U.S. Commercially Insured and Medicare Advantage Population.
Chung H; Deshpande G; Zolotarjova J; Quimbo RA; Kern DM; Cochetti PT; Willey VJ
J Manag Care Spec Pharm; 2019 May; 25(5):612-620. PubMed ID: 31039058
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study.
Sheer R; Bunniran S; Uribe C; Fiscella RG; Patel VD; Chandwani HS
J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282
[TBL] [Abstract][Full Text] [Related]
5. Consequences of patient access restrictions to branded oxycodone hydrochloride extended-release tablets on healthcare utilization and costs in US health plans.
Ben-Joseph R; Chen CC; De AP; Wade RL; Shah D
J Med Econ; 2014 Oct; 17(10):708-18. PubMed ID: 24888403
[TBL] [Abstract][Full Text] [Related]
6. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
7. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
8. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
9. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
10. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans.
Newman TV; Gabriel N; Liang Q; Drake C; El Khoudary SR; Good CB; Gellad WF; Hernandez I
J Manag Care Spec Pharm; 2022 Feb; 28(2):266-274. PubMed ID: 35098746
[No Abstract] [Full Text] [Related]
12. The Effect of Florida Medicaid's State-Mandated Formulary Provision on Prescription Drug Use and Health Plan Costs in a Medicaid Managed Care Plan.
Munshi KD; Mager D; Ward KM; Mischel B; Henderson RR
J Manag Care Spec Pharm; 2018 Feb; 24(2):124-131. PubMed ID: 29384030
[TBL] [Abstract][Full Text] [Related]
13. Estimation of Missed Statin Prescription Use in an Administrative Claims Dataset.
Wade RL; Patel JG; Hill JW; De AP; Harrison DJ
J Manag Care Spec Pharm; 2017 Sep; 23(9):936-942. PubMed ID: 28854076
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture.
Weaver J; Sajjan S; Lewiecki EM; Harris ST; Marvos P
J Manag Care Spec Pharm; 2017 Apr; 23(4):461-471. PubMed ID: 28345441
[TBL] [Abstract][Full Text] [Related]
15. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
16. Incremental Effect of the Addition of Prescriber Restrictions on a State Medicaid's Pharmacy-Only Patient Review and Restriction Program.
Keast SL; Pham T; Teel A; Nesser NJ
J Manag Care Spec Pharm; 2017 Aug; 23(8):875-883. PubMed ID: 28737989
[TBL] [Abstract][Full Text] [Related]
17. Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study.
Ems D; Racsa P; Anderson C; Gregory F; Worley K; Brill JV; Holt W
J Manag Care Spec Pharm; 2016 Jul; 22(7):863-71. PubMed ID: 27348286
[TBL] [Abstract][Full Text] [Related]
18. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
[TBL] [Abstract][Full Text] [Related]
19. Impact of Medicare Advantage Prescription Drug Plan Star Ratings on Enrollment before and after Implementation of Quality-Related Bonus Payments in 2012.
Li P; Doshi JA
PLoS One; 2016; 11(5):e0154357. PubMed ID: 27149092
[TBL] [Abstract][Full Text] [Related]
20. A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets.
Rubino M; Summers KH; Puenpatom A; Fu C; Ohsfeldt RL; Ben-Joseph RH
J Manag Care Pharm; 2011 Jun; 17(5):367-76. PubMed ID: 21657806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
